The efficacy of antioxidant treatment with mexidol forte in 250 patients with chronic cerebral venous insufficiency

Chukanova E.I.; Chukanova A.S.; Mamaeva Kh.I.

doi:https://doi.org/10.17116/jnevro202112103157

Chukanova E.I.

Pirogov Russian National Research Medical University

Chukanova A.S.

Pirogov Russian National Research Medical University

Mamaeva Kh.I.

Pirogov Russian National Research Medical University

The efficacy of antioxidant treatment with mexidol forte in 250 patients with chronic cerebral venous insufficiency

Authors:

Chukanova E.I., Chukanova A.S., Mamaeva Kh.I.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(3): 57‑63

DOI: 10.17116/jnevro202112103157

Read: 3315 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Chukanova EI, Chukanova AS, Mamaeva KhI. The efficacy of antioxidant treatment with mexidol forte in 250 patients with chronic cerebral venous insufficiency. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(3):57‑63. (In Russ.)
https://doi.org/10.17116/jnevro202112103157

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To study the efficacy and safety of complex treatment with 2-ethyl-3-hydroxy-6-methylpyridine (mexidol forte 250) and venotonic drugs L-lysine aescinat and diosmin/hesperidin in patients with chronic cerebral venous insufficiency (CCVI).

MATERIAL AND METHODS

One hundred and twenty CCVI patients with clinical and ultrasonic signs of cerebral venous discirculation were studied. Patients were stratified into group 1 (n=40) treated perorally with mexidol forte 250 and diosmin/hesperidin during 74 days in combination with two courses of L-lysine aescinat intravenously on the 1^st and 30^th days from baseline, group 2 (n=40) treated with mexidol forte 250 and diosmin/hesperidin during 74 days, group 3 (n=40) treated perorally with diosmin/hesperidin during 74 days.

RESULTS AND CONCLUSION

The efficacy and safety of the complex treatment of CCVI patients with venotonic drugs with the inclusion of mexidol forte 250 at a dose of 750 mg/day for 74 days is shown. The study demonstrates a significant positive effect of mexidol forte 250 on the dynamics of complaints and indicators of the neurological and psychoemotional status of patients. Monotherapy with the venotonic drug diosmin/hesperidin shows its insufficient efficacy.

Keywords:

chronic cerebral venous insufficiency

antioxidants

mexidol forte 250

venotonic drugs

L-lysine aescinat

diosmin/hesperidin

Authors:

Chukanova E.I.

Pirogov Russian National Research Medical University

Chukanova A.S.

Pirogov Russian National Research Medical University

Mamaeva Kh.I.

Pirogov Russian National Research Medical University

Received:

01.03.2021

Accepted:

09.03.2021

Close metadata

References:

Berdichevskii MYa. Venoznaya distsirkulyatornaya patologiya golovnogo mozga. M. 1989. (In Russ.).
Burtsev EM, Sergievskii SB, Asratyan SA. Varianty tserebral’noi arterial’noi i venoznoi angioarkhitektoniki pri distsirkulyatornoi entsefalopatii. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 1999;99(4):45-47. (In Russ.).
Gusev EI, Skvortsova VI. Ishemiya golovnogo mozga. M.: Meditsina; 2001. (In Russ.).
Belova LA. Venoznaya tserebral’naya distsirkulyatsiya pri khronicheskoi ishemii mozga: klinika, diagnostika, lechenie. Nevrologicheskii vestnik. 2010;27(2):62-67. (In Russ.).
Lektsiya po obshchei patologii narushenii krovo- i likvoroobrashcheniya [Internet]. Accessed Mar 16, 2021. (In Russ.). https://www.forens-med.ru/book.php?id=230
Perrin M, Ramelet AA. Pharmacological Treatment of Primary Chronic Venous Disease: Rationale, Results and Unanswered Questions. Eur J Vasc Endovasc Surg. 2011;41(1):117-125. https://doi.org/10.1016/j.ejvs.2010.09.025
Chukanova EI, Chukanova AS. Khronicheskaya ishemiya mozga (faktory riska, patogenez, klinika, lechenie). M.: AST 2016;345. (In Russ.).
Gusev EI, Chukanova EI, Chukanova AS. Khronicheskaya tserebrovaskulyarnaya nedostatochnost’ (faktory riska, patogenez, klinika, lechenie). M.: AST 2018;345. (In Russ.).
Kadykov AS, Manvelov LS, Shakhparonova NV. Khronicheskie sosudistye zabolevaniya golovnogo mozga. Distsirkulyatornaya entsefalopatiya. 4-e izd., pererab. i dop. M.: GEOTAR-Media; 2020. (In Russ.).
Abramenko YuV. Otsenka klinicheskoi effektivnosti, vazoaktivnogo i metabolicheskogo effektov meksidola u patsientov pozhilogo vozrasta s distsirkulyatornoi entsefalopatiei. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2011;111(11):35-40. (In Russ.).
Tanashyan MM, Lagoda OV, Antonova KV. Chronic cerebrovascular diseases against the background of metabolic syndrome: new approaches to treatment. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2012;112(11):21-26. (In Russ.).
Voronina TA. Meksidol: osnovnye neiropsikhotropnye effekty i mekhanizmy deistviya. Farmateka. 2009;6:28-31. (In Russ.).
Duma SN. Vozmozhnosti antioksidantnoi terapii pri astenii i kognitivnom defitsite u pozhilykh patsientov s khronicheskoi ishemiei mozga. Terapevticheskii arkhiv. 2013;85(12):100-105. (In Russ.).
Drozdova TV, Fit’mova OA, Fit’mova AA. Rol’ meksidola v terapii umerennykh kognitivnykh rasstroistv v ramkakh proyavleniya khronicheskoi nedostatochnosti mozgovogo krovoobrashcheniya. Farmateka. 2012;14:97-103. (In Russ.).
Smirnova IN, Fedorova TN, Tanashyan MM, Suslina ZA. Klinicheskaya effektivnost’ i antioksidantnaya aktivnost’ Meksidola pri khronicheskikh tserebrovaskulyarnykh zabolevaniyakh. Atmosfera. Nervnye bolezni. 2006;1:61-64. (In Russ.).
Belova AN. Shkaly, testy i oprosniki v nevrologii i neirokhirurgii. 3-e izd., pererab. i dop. M.: Prakticheskaya meditsina; 2018. (In Russ.).